Background: In a previous analysis of 12 cancers in the Cancer Prevention Study II (CPS-II) cohort including follow-up from 1982–2000, having both hay fever and asthma was associated with lower colorectal cancer mortality. The combination of these allergic conditions may be a marker for allergy-related immune responses that could inhibit colorectal carcinogenesis.

Methods: We examined the association of having both hay fever and asthma with colorectal cancer mortality among 1,023,191 participants in CPS-I, followed from 1959–1972, and 1,102,092 participants in CPS-II, now followed from 1982–2008. We also examined associations with colorectal cancer incidence among 174,917 participants in the CPS-II Nutrition Cohort, a subgroup of CPS-II followed from 1992–2007. During the follow-up, there were 5,644 colorectal cancer deaths in CPS-I, 13,558 colorectal cancer deaths in CPS-II, and 3,365 incident colorectal cancer cases in the CPS-II Nutrition Cohort. Cox proportional hazards regression was used to calculate multivariable-adjusted relative risks (RR) and 95% confidence intervals (CI).

Results: RRs for colorectal cancer mortality associated with having both asthma and hay fever, compared with neither condition, were 0.90 (95% CI, 0.74–1.09) in CPS-I, 0.79 (95% CI, 0.69–0.91) in CPS-II, and 0.83 (95% CI, 0.74–0.92) when results from both cohorts were combined in a meta-analysis. The corresponding RR for colorectal cancer incidence in the CPS-II Nutrition Cohort was 0.90 (95% CI, 0.71–1.14).

Conclusion: These results support an association between having both hay fever and asthma and modestly lower colorectal cancer mortality.

Impact: Research examining other potential markers of allergy-related immune response in relation to colorectal cancer is warranted. Cancer Epidemiol Biomarkers Prev; 22(4); 661–9. ©2013 AACR.

Hay fever (also known as allergic rhinitis) and asthma are both allergy-related conditions (1–3). Associations of hay fever and asthma with mortality from 12 cancers were examined in a previous analysis of the Cancer Prevention Study II (CPS-II; ref. 4). In that analysis, individuals who reported diagnoses of both hay fever and asthma had significantly lower overall cancer mortality [relative risk (RR) = 0.88; 95% confidence interval (CI), 0.83–0.93] and colorectal cancer mortality (RR = 0.76; 95% CI, 0.64–0.91) than those who reported neither hay fever nor asthma. Hay fever alone was associated with only slightly lower colorectal cancer mortality (RR = 0.92; 95% CI, 0.85–0.99), whereas no association was observed with asthma alone (RR = 1.04; 95% CI, 0.91–1.19).

A potential biologic explanation for lower colorectal cancer mortality among individuals with both hay fever and asthma is that these individuals are more likely than others to have atopy, a general predisposition to develop immunoglobulin E (IgE)-mediated (allergic) immune reactions (3), and therefore to develop IgE-mediated immune reactions against colorectal neoplasia. IgE-mediated immune reactions have been hypothesized to play an important role in immune surveillance against cancer in general (5) and could be important in inhibiting colorectal carcinogenesis in particular. In mice, treatment with IgE monoclonal antibodies that were specific for a colorectal tumor antigen inhibited the growth of human colorectal tumor xenografts (6). Recruitment of eosinophils to allergic sites is a key feature of IgE-mediated immune reactions (7), and eosinophils may have important antitumor effects (8), including cytotoxic effects on colorectal cancer cells (9). Eosinophil infiltration of colorectal adenomas is common and is associated with smaller size and less aggressive characteristics (10). Eosinophil infiltration of colorectal cancers is associated with better prognosis, independent of stage and grade (11, 12). The potential importance of eosinophils is also suggested by a recent cohort study showing an association between blood eosinophil count (typically elevated in atopic individuals; ref. 13) and substantially lower colorectal cancer incidence (14).

Epidemiologic studies to date have provided only limited support for an association between allergic conditions and lower risk of colorectal cancer. Other than CPS-II (4), only the Iowa Women's Health Study (IWHS; ref. 15), examined the association between having 2 or more allergic conditions and colorectal cancer risk. In the IWHS (15), having 2 or more allergic conditions was associated with approximately 40% lower colorectal cancer incidence. Although some studies of individual allergic conditions found associations with modestly lower risk of colorectal cancer (15–18), others did not (19–25), or found lower risk of rectal cancer, but not colon cancer (26).

Confirmation of the association of having both hay fever and asthma with lower risk of colorectal cancer mortality observed in CPS-II (4) is important given that it was observed in an analysis of multiple cancer outcomes, which raises the possibility that it could have been at least partly due to chance. In addition, results from other studies of allergic conditions and colorectal cancer are inconsistent. Confirmation of this association would also provide support for the hypothesis that IgE-mediated immune reactions can inhibit the development or progression of colorectal cancer. This in turn could have implications for research on vaccinations to stimulate or enhance IgE-mediated immune reactions against colorectal neoplasia (5).

To clarify whether having both hay fever and asthma is associated with colorectal cancer mortality, we examined this association in CPS-I, a large prospective study similar in design to CPS-II. In addition, we reexamined this association in CPS-II after extending follow-up from 16 years to 24 years, thereby adding more than 4,000 colorectal cancer deaths to the analysis. Finally, we examined the association between having both hay fever and asthma and colorectal incidence in the CPS-II Nutrition Cohort to explore whether the association previously observed for colorectal cancer mortality might also be apparent for colorectal cancer incidence.

Analyses of colorectal cancer mortality or incidence were conducted in 3 American Cancer Society prospective cohort studies, CPS-I, CPS-II, and the CPS-II Nutrition Cohort, a subgroup of CPS-II. Hereafter, the larger “parent” CPS-II cohort will be referred to as the CPS-II Mortality Cohort. Each of these cohorts is described in more detail below.

CPS-I

CPS-I included 1,051,031 participants (456,487 men and 594,544 women) from 25 U.S. states who were at least 30 years of age at enrollment in 1959 (27, 28). Participants were enrolled by American Cancer Society volunteers who asked their friends and neighbors to complete a self-administered questionnaire that included information on demographic, medical, and lifestyle factors. Those who self-reported any cancer other than nonmelanoma skin cancer at enrollment (N = 27,840) were excluded, leaving 1,023,191 participants (449,320 men and 573,871 women) in the analysis.

Hay fever and asthma were self-reported on the 1959 baseline questionnaire. A list of medical conditions including “hay fever” and “asthma” was provided, and participants were asked to “mark each of the following diseases you have ever had.”

Follow-up for cancer mortality was based on ascertainment of vital status by volunteers and subsequent verification based on review of death certificates (27). For the first 6 years of CPS-I, volunteers made personal inquiries annually to determine the vital status of the participants they had enrolled. Follow-up by the volunteers was done again during 1971 and 1972 (27). After 13 years of follow-up, 731,273 participants (69.6%) were still living, 188,056 (17.9%) had died, 75,934 (7.2%) were lost to follow-up, and 55,768 (5.3%) had follow-up truncated in 1965 because of the inability of the American Cancer Society volunteer organizations in some locations to continue the study. Death certificates or multiple causes of death codes were obtained for 97% of known deaths. Colorectal cancer deaths were those assigned codes 153 and 154 using the International Classification of Diseases, Seventh Revision (ICD-7; ref. 29). Among participants included in this analysis, 5,644 deaths from colorectal cancer were identified during follow-up through September 30, 1972.

CPS-II Mortality Cohort

The CPS-II Mortality Cohort was similar in design to CPS-I and included 1,184,418 participants (508,237 men and 676,181 women) from 50 U.S. states, the District of Columbia and Puerto Rico, who were at least 30 years of age at enrollment in 1982 (30). Participants were enrolled by American Cancer Society volunteers who asked their friends and neighbors to complete a 4 page self-administered questionnaire that included information on demographic, medical, and lifestyle factors. Those who self-reported any cancer other than nonmelanoma skin cancer at enrollment in 1982 (N = 82,326) were excluded, leaving 1,102,092 participants (483,005 men and 619,087 women) in the analysis.

Hay fever and asthma were self-reported on the 1982 baseline questionnaire. A list of medical conditions, including “hay fever” and “asthma,” was provided, and the participants were asked to mark diseases or conditions “for which you have ever been diagnosed by a doctor.”

To ascertain the vital status of CPS-II Mortality Cohort participants, American Cancer Society volunteers made personal inquiries in September 1984, 1986, and 1988 to determine whether the participants they had enrolled were alive or dead, and recorded the dates and places of deaths. Reported deaths were verified by obtaining death certificates. At completion of the 1988 follow-up, vital status was known for 98.2% of the cohort. Linkage to the National Death Index was used to identify deaths that occurred between September 1988 and December 2008 and to identify deaths among 21,704 participants lost to follow-up between 1982 and 1988 (31). Death certificates or codes for the cause of death were obtained for more than 99% of all known deaths. The underlying cause of death was defined according to the ICD-9(32) for deaths occurring from 1982 through 1998 and the ICD-10 (33) for deaths occurring from 1999 through 2008. Colorectal cancer deaths were defined as ICD-9 codes 153 (colon) and 154 (rectal), or as ICD-10 codes C18 (colon) and C19, C20 (rectal). Among participants included in this analysis, 13,558 deaths from colorectal cancer were identified during follow-up through December 31, 2008. Of these, 9,404 occurred during follow-up from 1982 through 2000, the follow-up period included in the previous analysis (4), and 4,154 occurred during follow-up from 2001 through 2008.

CPS-II Nutrition Cohort

The CPS-II Nutrition Cohort is a prospective study of cancer incidence, established in 1992, which includes 184,188 CPS-II Mortality Cohort participants from 21 U.S. states (34). At enrollment in 1992 or 1993, participants completed a mailed self-administered questionnaire including information on demographic, medical, and lifestyle factors. Follow-up questionnaires were sent in 1997 and every 2 years thereafter to update health-related information and ascertain newly diagnosed cancers. The response rate for each follow-up questionnaire was at least 87%. This analysis excludes participants with a history of colorectal cancer at enrollment (N = 2,894), those who were lost to follow-up before contributing any person-time to the analysis (alive at the time of the first follow-up questionnaire in 1997, but did not complete the 1997 or any subsequent follow-up questionnaire, N = 6,170), and those who self-reported a colorectal cancer on the first follow-up survey that could not be verified through medical records or cancer registry linkage (N = 207), leaving 174,917 participants (81,574 men and 93,343 women) in this analysis. Follow-up time began at enrollment in 1992 or 1993 and continued until diagnosis with colorectal cancer, return date of the last completed follow-up questionnaire, death, or the end of the study follow-up period on June 30, 2007.

There were no questions about hay fever or asthma on the 1992 enrollment questionnaire or on later follow-up questionnaires. Hay fever and asthma status are therefore based on what participants reported on the 1982 CPS-II Mortality Cohort questionnaire, as described above.

Of the 3,365 incident colorectal cancer cases included in this analysis, 2,729 were initially identified by self-report on the follow-up questionnaires and were subsequently verified by obtaining medical records, or through linkage with state cancer registries when complete medical records could not be obtained (34). Ascertainment of cancer by self-report is estimated to have a sensitivity of 93% in the Nutrition Cohort (35). An additional 636 cases of colorectal cancer were identified through linkage with the National Death Index (31), of which 492 were verified through subsequent linkage with state cancer registries. Both the CPS-II Nutrition Cohort and the CPS-II Mortality Cohort have been approved by the Emory University Institutional Review Board (Atlanta, GA).

Statistical analyses

A variable for allergic conditions was created that included 4 categories, no hay fever or asthma (the referent group), hay fever only, asthma only, and both hay fever and asthma. Cox proportional hazards modeling was used to estimate RR while adjusting for potential confounders. Time since enrollment was used as the underlying time axis. All multivariable models were adjusted for age, sex, race, education, body mass index (BMI), physical activity, smoking, and use of aspirin. In the CPS-II Nutrition Cohort, analyses were also adjusted for history of colorectal endoscopy. However, because information on endoscopy was first collected on the 1997 follow-up questionnaire, rather than at enrollment in 1992, only follow-up time after completion of the 1997 questionnaire could be adjusted for this factor. Age was adjusted for using the stratified Cox procedure (36) with one-year strata. Aspirin use was categorized as never, seldom, or often in CPS-I (the categories provided on the questionnaire) or as unknown, as no regular use, occasional use, 1 to 14, 15 to 29, 30 times or more per month or unknown in the CPS-II Mortality Cohort, and as no regular use, 1 to 14, 15 to 29, 30 to 59, 60 pills or more per month or unknown in the CPS-II Nutrition Cohort. All other covariates were modeled using the categories shown in Table 1. Further adjustment for alcohol use, diabetes, vegetable intake (in all 3 cohorts), red and processed meat intake, and use of oral contraceptives and postmenopausal hormones (assessed only in CPS-II and the CPS-II Nutrition Cohort) had negligible impact on risk estimates, and these factors were not included in the final multivariable models.

Table 1.

Baseline characteristics by asthma and hay fever status in CPS-I, the CPS-II Mortality Cohort, and the CPS-II Nutrition Cohorta

CPS-I 1959CPS-II Mortality Cohort 1982CPS-II Nutrition Cohort 1992
No asthma or hay fever N = 883,389 (%)Asthma only N = 27,732 (%)Hay fever only N = 87,560 (%)Hay fever and asthma N = 24,510 (%)No asthma or hay fever N = 947,073 (%)Asthma only N = 26,094 (%)Hay fever only N = 105,028 (%)Hay fever and asthma N = 23,897 (%)No asthma or hay fever N = 148,709 (%)Asthma only N = 3,690 (%)Hay fever only N = 18,160 (%)Hay fever and asthma N = 4,358 (%)
Age, y 
 30–39 8.1 6.5 10.3 9.7 4.6 5.6 6.1 6.5 0.0 0.0 0.0 0.0 
 40–49 30.7 26.5 35.5 34.9 20.2 20.3 25.1 25.7 1.1 1.5 1.4 1.6 
 50–59 34.1 33.3 33.7 32.9 35.8 34.5 36.7 37.1 28.0 28.6 32.4 33.2 
 60–69 18.7 22.2 14.9 16.1 26.7 26.6 22.8 22.2 53.4 53.8 51.5 51.3 
 70–79 6.9 9.5 4.7 5.4 10.6 11.0 8.1 7.2 17.1 15.5 14.4 13.7 
 ≥80 1.5 2.0 0.9 1.0 2.1 2.1 1.3 1.3 0.5 0.6 0.3 0.2 
Sex 
 Female 55.8 50.7 59.5 59.0 55.5 55.2 61.4 60.4 52.9 51.4 56.6 56.8 
 Male 44.2 49.3 40.5 41.0 44.5 44.8 38.6 39.6 47.1 48.6 43.4 43.2 
Race 
 White 96.5 96.2 96.3 97.0 93.3 91.1 92.6 93.7 97.5 96.8 96.6 96.8 
 Black 2.4 2.7 2.6 1.9 4.5 6.0 4.5 4.0 1.4 1.7 1.4 1.2 
 Other or unknown 1.2 1.1 1.1 1.1 2.3 3.0 2.8 2.3 1.2 1.5 2.0 2.0 
Education 
 Less than high school 40.8 47.5 33.0 33.6 15.0 17.2 10.2 10.3 7.0 6.7 3.9 3.1 
 High school graduate 22.7 20.3 21.6 20.9 26.5 23.9 20.8 19.5 26.8 24.6 19.2 18.3 
 Some college 19.6 18.3 23.1 23.2 28.2 28.6 30.1 30.6 28.8 29.7 29.0 29.7 
 College graduate 15.9 12.8 21.4 21.5 15.5 14.6 19.2 18.9 19.4 19.2 23.9 23.2 
 Graduate schoolb – – – – 13.3 14.0 18.4 19.3 17.3 19.0 23.5 25.3 
 Unknown 1.0 1.1 0.8 0.9 1.6 1.7 1.3 1.4 0.7 0.8 0.5 0.4 
BMI (kg/m2
 <22.5 25.3 25.9 28.6 27.8 24.9 23.7 27.9 26.5 19.6 19.9 22.5 22.0 
 22.5–<25.0 26.1 23.8 27.5 26.2 25.6 24.4 27.1 26.0 24.4 24.4 26.5 25.8 
 25.0–<27.5 23.8 22.4 22.6 22.8 24.6 23.8 23.2 23.2 25.4 23.7 24.9 24.5 
 27.5–<30.0 10.2 10.8 8.9 9.4 11.7 12.0 10.3 11.2 14.1 13.7 12.3 12.1 
 ≥30.0 7.6 9.9 6.1 7.3 10.9 13.6 9.4 11.0 14.9 16.9 12.7 14.2 
 Unknown 7.0 7.2 6.3 6.5 2.3 2.5 2.0 2.0 1.5 1.4 1.2 1.5 
Physical activityc 
 None 2.3 3.2 2.0 2.6 2.2 3.2 1.9 2.6 10.8 12.0 8.8 11.0 
 Slight 16.6 18.9 18.6 19.8 22.6 26.2 23.7 26.2 29.6 29.8 29.0 30.7 
 Moderate 67.0 63.1 67.4 65.1 64.8 60.9 65.3 62.3 47.6 46.0 49.9 47.2 
 Heavy 11.6 12.7 10.1 10.8 8.7 7.9 7.5 7.3 10.3 10.4 10.8 10.1 
 Unknown 2.5 2.1 1.9 1.8 1.7 1.8 1.5 1.6 1.6 1.8 1.4 1.1 
Cigarette smoking 
 Never 50.8 40.9 55.5 53.6 43.5 39.7 51.3 48.5 42.8 39.9 50.2 47.9 
 Former 10.9 13.0 12.2 13.6 27.5 32.1 27.1 30.3 46.7 50.6 42.5 45.1 
 Current 35.6 42.9 29.6 30.0 22.5 21.5 15.6 15.4 9.1 8.2 6.0 5.9 
 Unknown 2.6 3.1 2.7 2.9 6.5 6.6 6.0 5.8 1.3 1.2 1.3 1.1 
CPS-I 1959CPS-II Mortality Cohort 1982CPS-II Nutrition Cohort 1992
No asthma or hay fever N = 883,389 (%)Asthma only N = 27,732 (%)Hay fever only N = 87,560 (%)Hay fever and asthma N = 24,510 (%)No asthma or hay fever N = 947,073 (%)Asthma only N = 26,094 (%)Hay fever only N = 105,028 (%)Hay fever and asthma N = 23,897 (%)No asthma or hay fever N = 148,709 (%)Asthma only N = 3,690 (%)Hay fever only N = 18,160 (%)Hay fever and asthma N = 4,358 (%)
Age, y 
 30–39 8.1 6.5 10.3 9.7 4.6 5.6 6.1 6.5 0.0 0.0 0.0 0.0 
 40–49 30.7 26.5 35.5 34.9 20.2 20.3 25.1 25.7 1.1 1.5 1.4 1.6 
 50–59 34.1 33.3 33.7 32.9 35.8 34.5 36.7 37.1 28.0 28.6 32.4 33.2 
 60–69 18.7 22.2 14.9 16.1 26.7 26.6 22.8 22.2 53.4 53.8 51.5 51.3 
 70–79 6.9 9.5 4.7 5.4 10.6 11.0 8.1 7.2 17.1 15.5 14.4 13.7 
 ≥80 1.5 2.0 0.9 1.0 2.1 2.1 1.3 1.3 0.5 0.6 0.3 0.2 
Sex 
 Female 55.8 50.7 59.5 59.0 55.5 55.2 61.4 60.4 52.9 51.4 56.6 56.8 
 Male 44.2 49.3 40.5 41.0 44.5 44.8 38.6 39.6 47.1 48.6 43.4 43.2 
Race 
 White 96.5 96.2 96.3 97.0 93.3 91.1 92.6 93.7 97.5 96.8 96.6 96.8 
 Black 2.4 2.7 2.6 1.9 4.5 6.0 4.5 4.0 1.4 1.7 1.4 1.2 
 Other or unknown 1.2 1.1 1.1 1.1 2.3 3.0 2.8 2.3 1.2 1.5 2.0 2.0 
Education 
 Less than high school 40.8 47.5 33.0 33.6 15.0 17.2 10.2 10.3 7.0 6.7 3.9 3.1 
 High school graduate 22.7 20.3 21.6 20.9 26.5 23.9 20.8 19.5 26.8 24.6 19.2 18.3 
 Some college 19.6 18.3 23.1 23.2 28.2 28.6 30.1 30.6 28.8 29.7 29.0 29.7 
 College graduate 15.9 12.8 21.4 21.5 15.5 14.6 19.2 18.9 19.4 19.2 23.9 23.2 
 Graduate schoolb – – – – 13.3 14.0 18.4 19.3 17.3 19.0 23.5 25.3 
 Unknown 1.0 1.1 0.8 0.9 1.6 1.7 1.3 1.4 0.7 0.8 0.5 0.4 
BMI (kg/m2
 <22.5 25.3 25.9 28.6 27.8 24.9 23.7 27.9 26.5 19.6 19.9 22.5 22.0 
 22.5–<25.0 26.1 23.8 27.5 26.2 25.6 24.4 27.1 26.0 24.4 24.4 26.5 25.8 
 25.0–<27.5 23.8 22.4 22.6 22.8 24.6 23.8 23.2 23.2 25.4 23.7 24.9 24.5 
 27.5–<30.0 10.2 10.8 8.9 9.4 11.7 12.0 10.3 11.2 14.1 13.7 12.3 12.1 
 ≥30.0 7.6 9.9 6.1 7.3 10.9 13.6 9.4 11.0 14.9 16.9 12.7 14.2 
 Unknown 7.0 7.2 6.3 6.5 2.3 2.5 2.0 2.0 1.5 1.4 1.2 1.5 
Physical activityc 
 None 2.3 3.2 2.0 2.6 2.2 3.2 1.9 2.6 10.8 12.0 8.8 11.0 
 Slight 16.6 18.9 18.6 19.8 22.6 26.2 23.7 26.2 29.6 29.8 29.0 30.7 
 Moderate 67.0 63.1 67.4 65.1 64.8 60.9 65.3 62.3 47.6 46.0 49.9 47.2 
 Heavy 11.6 12.7 10.1 10.8 8.7 7.9 7.5 7.3 10.3 10.4 10.8 10.1 
 Unknown 2.5 2.1 1.9 1.8 1.7 1.8 1.5 1.6 1.6 1.8 1.4 1.1 
Cigarette smoking 
 Never 50.8 40.9 55.5 53.6 43.5 39.7 51.3 48.5 42.8 39.9 50.2 47.9 
 Former 10.9 13.0 12.2 13.6 27.5 32.1 27.1 30.3 46.7 50.6 42.5 45.1 
 Current 35.6 42.9 29.6 30.0 22.5 21.5 15.6 15.4 9.1 8.2 6.0 5.9 
 Unknown 2.6 3.1 2.7 2.9 6.5 6.6 6.0 5.8 1.3 1.2 1.3 1.1 

aAll percentages standardized to the age and sex distribution of each study cohort.

bInformation on graduate school education not collected in CPS-I.

cCategories as worded on the CPS-I and CPS-II questionnaires. For the CPS-II Nutrition Cohort, levels correspond to 0, <7, 7 −<28, and ≥28 METs (metabolic equivalents) per week.

In selected analyses, associations with colorectal cancer mortality in CPS-I and the CPS-II Mortality Cohort were combined in a meta-analysis. A fixed-effects model was used because of the similar design of these 2 cohorts (37).

Because IgE-mediated immune reactions may differ by age (38) and sex (39), and because self-reported asthma in smokers might reflect smoking-related respiratory problems, possible differences in the association of having both asthma and hay fever with risk of colorectal cancer by attained age, sex, and smoking status were examined. We modeled multiplicative interaction terms between a dichotomous variable for having both hay fever and asthma, and attained age (modeled as a continuous variable), sex, and smoking status (never, former, current) and calculated a P value for interaction by comparing the likelihood ratio statistic from models with and without interaction terms.

The prevalence of having both hay fever and asthma was similar across the cohorts included in this analysis (Table 1). In the CPS-I cohort, 2.4% reported having both hay fever and asthma, whereas 85.9% reported having neither allergic condition. Similarly, in the CPS-II Mortality Cohort and the CPS-II Nutrition Cohort, 2.2% and 2.5% reported having both hay fever and asthma, whereas 85.9% and 85.0% reported having neither allergic condition, respectively. In each of the cohorts, participants were predominantly White, aged 40 years or older at enrollment, and slightly more than half were women (Table 1). Compared with participants with neither asthma nor hay fever, those with both asthma and hay fever were more likely to be well educated and less likely to be current smokers. BMI and physical activity were generally similar to asthma and hay fever status, although participants with asthma only were more likely than other participants to be obese. In the CPS-II Nutrition Cohort, the prevalence of a history of colorectal endoscopy in 1997 (the year this was first reported) was slightly higher among individuals with asthma and hay fever (59.9%) than among those with neither condition (55.3%).

Having both asthma and hay fever, compared with having neither, was associated with nonstatistically significantly lower colorectal cancer mortality in CPS-I (RR = 0.90; 95% CI, 0.74–1.09) and statistically significantly lower colorectal cancer mortality in the CPS-II Mortality Cohort (RR = 0.79; 95% CI, 0.69–0.91; Table 2). This association did not differ between CPS-I and the CPS-II Mortality Cohort (P = 0.28 for heterogeneity). In a meta-analysis of results from CPS-I and the CPS-II Mortality Cohort, having both hay fever and asthma was associated with statistically significantly lower colorectal cancer mortality (RR = 0.83; 95% CI, 0.74–0.92).

Table 2.

Colorectal cancer incidence or mortality by asthma and hay fever status, in CPS-I, the CPS-II Mortality Cohort, and the CPS-II Nutrition Cohort

CPS-I Mortality, 1959—72CPS-II Mortality Cohort Mortality, 1982–2008CPS-II Nutrition Cohort, Incidence, 1992–2007
DeathsPerson-yearsRR (95% CI)aDeathsPerson-yearsRR (95% CI)aCasesPerson-yearsRR (95% CI)b
Asthma and hay fever status 
 No asthma or hay fever 4,965 9,864,615 1.00 (ref) 11,976 20,086,992 1.00 (ref) 2,923 1,801,429 1.00 (ref) 
 Asthma only 154 287,454 0.97 (0.82–1.14) 302 522,659 1.01 (0.90–1.13) 65 44,228 0.92 (0.72–1.18) 
 Hay fever only 417 998,750 0.97 (0.88–1.07) 1,078 2,354,617 0.92 (0.86–0.98) 307 227,878 0.95 (0.85–1.07) 
 Hay fever and asthma 108 275,117 0.90 (0.74–1.09) 202 529,567 0.79 (0.69–0.91) 70 54,525 0.90 (0.71–1.14) 
CPS-I Mortality, 1959—72CPS-II Mortality Cohort Mortality, 1982–2008CPS-II Nutrition Cohort, Incidence, 1992–2007
DeathsPerson-yearsRR (95% CI)aDeathsPerson-yearsRR (95% CI)aCasesPerson-yearsRR (95% CI)b
Asthma and hay fever status 
 No asthma or hay fever 4,965 9,864,615 1.00 (ref) 11,976 20,086,992 1.00 (ref) 2,923 1,801,429 1.00 (ref) 
 Asthma only 154 287,454 0.97 (0.82–1.14) 302 522,659 1.01 (0.90–1.13) 65 44,228 0.92 (0.72–1.18) 
 Hay fever only 417 998,750 0.97 (0.88–1.07) 1,078 2,354,617 0.92 (0.86–0.98) 307 227,878 0.95 (0.85–1.07) 
 Hay fever and asthma 108 275,117 0.90 (0.74–1.09) 202 529,567 0.79 (0.69–0.91) 70 54,525 0.90 (0.71–1.14) 

aRR for colorectal cancer mortality adjusted for age, sex, race, education, BMI, physical activity, smoking, and aspirin use.

bRR for incident colorectal cancer, adjusted for age, sex, race, education, BMI, physical activity, smoking, aspirin use, and history of colorectal endoscopy.

In the CPS-II Nutrition Cohort, having both hay fever and asthma was associated with nonstatistically significantly lower incidence of colorectal cancer (RR = 0.90; 95% CI, 0.71–1.14). We also examined associations with colorectal cancer mortality within the CPS-II Nutrition Cohort to determine whether associations with colorectal cancer mortality might be stronger than those with colorectal incidence within the same study population. Having both hay fever and asthma was not associated with colorectal cancer mortality within the CPS-II Nutrition Cohort although statistical precision was limited (RR = 0.99; 95% CI, 0.69–1.44, in analyses including 29 deaths among participants with both conditions).

In each of the 3 cohorts in this analysis, multivariable-adjusted RRs for having both hay fever and asthma (shown in Table 2) were slightly closer to the null than results adjusted only for age and sex. RRs for having both hay fever and asthma, adjusted for only age and sex, were 0.89 (95% CI 0.74–1.08) in CPS-I, 0.75 (95% CI 0.65–0.86) in the CPS-II Mortality Cohort, and 0.84 (95% CI 0.67–1.07) in the CPS-II Nutrition Cohort.

Because the association between hay fever and asthma and colorectal cancer mortality during the first 18 years of follow-up of the CPS-II Mortality Cohort has been previously reported (4), we examined this association separately during follow-up time included in the previous report (1982–2000) and during more recent follow-up (2001–2008). The RR of colorectal cancer mortality associated with having both hay fever and asthma during follow-up from 1982–2000 was 0.77 (95% CI 0.65–0.91), nearly identical to that previously reported (4). The corresponding RR during follow-up from 2001–2008 was similar in magnitude, although not statistically significant (RR = 0.83; 95% CI, 0.66–1.06).

Because the CPS-II Nutrition Cohort is a subgroup of the CPS-II Mortality Cohort, results from analyses of these 2 cohorts are not statistically independent. A total of 950 individuals were included as both incident cases of colorectal cancer in the CPS-II Nutrition Cohort and colorectal cancer deaths in the CPS-II Mortality Cohort. We conducted a sensitivity analysis censoring participants from the CPS-II Mortality Cohort on the date they entered the Nutrition Cohort analysis to obtain a statistically independent risk estimate. Results of this sensitivity analysis were similar to those from the main CPS-II Mortality Cohort analysis (RR = 0.78; 95% CI, 0.67–0.90 for having both hay fever and asthma compared with neither).

Associations with having both hay fever and asthma seemed generally similar for colon cancer and rectal cancer (Table 3). Having hay fever alone was much more common than having both hay fever and asthma and therefore could be examined with more statistical power in subsite analyses. Having hay fever alone was associated with lower risk of rectal cancer mortality (RR = 0.84; 95% CI, 0.73–0.97 in a meta-analysis of CPS-I and the CPS-II Mortality Cohort) but was not associated with colon cancer mortality (RR = 0.95; 95% CI, 0.89–1.01). Associations of having both asthma and hay fever with colorectal cancer mortality or incidence seemed similar in analyses stratified by attained age, sex, and smoking status (Table 4).

Table 3.

Colon and rectal cancer incidence or mortality by asthma and hay fever status, in CPS-I, the CPS-II Mortality Cohort, and the CPS-II Nutrition Cohort

CPS-I Mortality, 1959–72CPS-II Mortality Cohort Mortality, 1982–2008CPS-II Nutrition Cohort, Incidence, 1992–2007
DeathsPerson-yearsRR (95% CI)aDeathsPerson-yearsRR (95% CI)aCasesPerson-yearsRR (95% CI)b
Colon 
 No asthma or hay fever 3,895 9,864,615 1.00 (ref) 10,396 20,086,992 1.00 (ref) 2,182 1,801,429 1.00 (ref) 
 Asthma only 110 287,454 0.89 (0.74–1.07) 260 522,659 1.00 (0.88–1.13) 44 44,228 0.84 (0.62–1.13) 
 Hay fever only 339 998,750 1.00 (0.89–1.12) 951 2,354,617 0.93 (0.87–1.00) 235 227,878 0.97 (0.84–1.11) 
 Hay fever and asthma 91 275,117 0.96 (0.78–1.18) 171 529,567 0.77 (0.66–0.90) 55 54,525 0.94 (0.72–1.23) 
Rectal 
 No asthma or hay fever 1,070 9,864,615 1.00 (ref) 1,580 20,086,992 1.00 (ref) 741 1,801,429 1.00 (ref) 
 Asthma only 44 287,454 1.24 (0.92–1.68) 42 522,659 1.07 (0.79–1.46) 21 44,228 1.17 (0.76–1.80) 
 Hay fever only 78 998,750 0.87 (0.69–1.09) 127 2,354,617 0.82 (0.69–0.99) 72 227,878 0.91 (0.71–1.16) 
 Hay fever and asthma 17 275,117 0.68 (0.42–1.09) 31 529,567 0.92 (0.65–1.32) 15 54,525 0.78 (0.47–1.30) 
CPS-I Mortality, 1959–72CPS-II Mortality Cohort Mortality, 1982–2008CPS-II Nutrition Cohort, Incidence, 1992–2007
DeathsPerson-yearsRR (95% CI)aDeathsPerson-yearsRR (95% CI)aCasesPerson-yearsRR (95% CI)b
Colon 
 No asthma or hay fever 3,895 9,864,615 1.00 (ref) 10,396 20,086,992 1.00 (ref) 2,182 1,801,429 1.00 (ref) 
 Asthma only 110 287,454 0.89 (0.74–1.07) 260 522,659 1.00 (0.88–1.13) 44 44,228 0.84 (0.62–1.13) 
 Hay fever only 339 998,750 1.00 (0.89–1.12) 951 2,354,617 0.93 (0.87–1.00) 235 227,878 0.97 (0.84–1.11) 
 Hay fever and asthma 91 275,117 0.96 (0.78–1.18) 171 529,567 0.77 (0.66–0.90) 55 54,525 0.94 (0.72–1.23) 
Rectal 
 No asthma or hay fever 1,070 9,864,615 1.00 (ref) 1,580 20,086,992 1.00 (ref) 741 1,801,429 1.00 (ref) 
 Asthma only 44 287,454 1.24 (0.92–1.68) 42 522,659 1.07 (0.79–1.46) 21 44,228 1.17 (0.76–1.80) 
 Hay fever only 78 998,750 0.87 (0.69–1.09) 127 2,354,617 0.82 (0.69–0.99) 72 227,878 0.91 (0.71–1.16) 
 Hay fever and asthma 17 275,117 0.68 (0.42–1.09) 31 529,567 0.92 (0.65–1.32) 15 54,525 0.78 (0.47–1.30) 

aRR for colorectal cancer mortality adjusted for age, sex, race, education, BMI, physical activity, smoking, and aspirin use.

bRR for incident colorectal cancer, adjusted for age, sex, race, education, BMI, physical activity, smoking, aspirin use, and history of colorectal endoscopy.

Table 4.

Colorectal cancer incidence or mortality associated with asthma and hay fever status, by age, sex, and smoking status in CPS-I, the CPS-II Mortality Cohort, and the CPS-II Nutrition Cohort

CPS-I Mortality, 1959–72CPS-II Mortality Cohort Mortality, 1982–2008CPS-II Nutrition Cohort, Incidence, 1992–2007
DeathsPerson-yearsRR (95% CI)aDeathsPerson-yearsRR (95% CI)aCasesPerson-yearsRR (95% CI)b
Age < 70 years 
 No asthma or hay fever 2,751 8,389,693 1.00 (ref) 3,427 11,599,057 1.00 (ref) 1,062 904,787 1.00 (ref) 
 Asthma only 68 236,865 0.83 (0.65–1.05) 100 316,244 1.08 (0.89–1.32) 25 23,206 0.94 (0.63–1.40) 
 Hay fever only 247 887,407 0.93 (0.81–1.06) 330 1,461,652 0.88 (0.78–0.98) 108 123,110 0.85 (0.69–1.03) 
 Hay fever and asthma 64 242,931 0.87 (0.68–1.12) 57 338,216 0.65 (0.50–0.85) 26 30,132 0.83 (0.56–1.22) 
Age ≥ 70 years 
 No asthma or hay fever 2,214 1,474,921 1.00 (ref) 8,549 8,487,935 1.00 (ref) 1,861 896,642 1.00 (ref) 
 Asthma only 86 50,590 1.12 (0.90–1.39) 202 206,414 0.98 (0.85–1.12) 40 21,022 0.92 (0.67–1.25) 
 Hay fever only 170 111,342 1.04 (0.89–1.22) 748 892,966 0.94 (0.87–1.01) 199 104,767 1.02 (0.89–1.19) 
 Hay fever and asthma 44 32,186 0.94 (0.69–1.26) 145 191,351 0.86 (0.73–1.01) 44 24,393 0.95 (0.71–1.28) 
Pinteractionc   0.83   0.10   0.89 
Men 
 No asthma or hay fever 2,374 4,233,190 1.00 (ref) 6,074 8,432,777 1.00 (ref) 1,627 816,578 1.00 (ref) 
 Asthma only 93 135,875 1.11 (0.90–1.36) 150 222,298 1.00 (0.85–1.17) 36 20,771 0.92 (0.66–1.28) 
 Hay fever only 206 388,657 1.04 (0.90–1.20) 476 868,136 0.90 (0.82–0.99) 148 94,757 0.93 (0.79–1.11) 
 Hay fever and asthma 44 106,957 0.81 (0.60–1.09) 89 200,398 0.76 (0.62–0.94) 35 22,633 0.92 (0.66–1.28) 
Women 
 No asthma or hay fever 2,591 5,631,425 1.00 (ref) 5,902 11,654,214 1.00 (ref) 1,296 984,851 1.00 (ref) 
 Asthma only 61 151,580 0.82 (0.63–1.05) 152 300,361 1.02 (0.87–1.20) 29 23,457 0.94 (0.65–1.37) 
 Hay fever only 211 610,093 0.91 (0.79–1.05) 602 1,486,482 0.94 (0.86–1.02) 159 133,120 0.99 (0.84–1.17) 
 Hay fever and asthma 64 168,159 0.97 (0.76–1.25) 113 329,169 0.82 (0.68–0.98) 35 31,893 0.90 (0.64–1.26) 
Pinteractionc   0.26   0.66   0.99 
Never smoker 
 No asthma or hay fever 2,504 4,580,901 1.00 (ref) 4,399 8,364,584 1.00 (ref) 1,009 746,143 1.00 (ref) 
 Asthma only 67 111,639 0.98 (0.77–1.25) 110 201,520 1.06 (0.87–1.28) 22 16,872 0.98 (0.64–1.50) 
 Hay fever only 210 497,073 0.95 (0.82–1.09) 480 1,145,024 0.95 (0.87–1.05) 128 109,487 0.96 (0.80–1.15) 
 Hay fever and asthma 65 133,796 1.06 (0.82–1.35) 93 242,000 0.89 (0.73–1.10) 27 24,503 0.89 (0.60–1.30) 
Former smoker 
 No asthma or hay fever 500 914,174 1.00 (ref) 3,439 5,411,919 1.00 (ref) 1,392 777,121 1.00 (ref) 
 Asthma only 13 31,205 0.67 (0.38–1.16) 88 161,631 0.89 (0.72–1.10) 30 20,985 0.82 (0.57–1.18) 
 Hay fever only 50 107,792 0.98 (0.74–1.32) 306 631,797 0.92 (0.82–1.03) 147 90,787 1.02 (0.86–1.21) 
 Hay fever and asthma 32,948 0.57 (0.29–1.10) 57 158,607 0.71 (0.55–0.92) 33 23,041 0.91 (0.64–1.28) 
Current smoker 
 No asthma or hay fever 1,124 3,224,821 1.00 (ref) 2,489 4,098,268 1.00 (ref) 274 144,225 1.00 (ref) 
 Asthma only 47 109,356 1.09 (0.82–1.46) 61 102,513 1.10 (0.85–1.42) 3,191 1.33 (0.66–2.70) 
 Hay fever only 86 285,309 0.97 (0.78–1.21) 156 345,655 0.86 (0.73–1.01) 19 12,481 0.88 (0.55–1.41) 
 Hay fever and asthma 22 78,365 0.91 (0.60–1.39) 31 77,124 0.79 (0.56–1.13) 3,044 0.21 (0.03–1.47) 
Pinteractionc   0.17   0.42   0.15 
CPS-I Mortality, 1959–72CPS-II Mortality Cohort Mortality, 1982–2008CPS-II Nutrition Cohort, Incidence, 1992–2007
DeathsPerson-yearsRR (95% CI)aDeathsPerson-yearsRR (95% CI)aCasesPerson-yearsRR (95% CI)b
Age < 70 years 
 No asthma or hay fever 2,751 8,389,693 1.00 (ref) 3,427 11,599,057 1.00 (ref) 1,062 904,787 1.00 (ref) 
 Asthma only 68 236,865 0.83 (0.65–1.05) 100 316,244 1.08 (0.89–1.32) 25 23,206 0.94 (0.63–1.40) 
 Hay fever only 247 887,407 0.93 (0.81–1.06) 330 1,461,652 0.88 (0.78–0.98) 108 123,110 0.85 (0.69–1.03) 
 Hay fever and asthma 64 242,931 0.87 (0.68–1.12) 57 338,216 0.65 (0.50–0.85) 26 30,132 0.83 (0.56–1.22) 
Age ≥ 70 years 
 No asthma or hay fever 2,214 1,474,921 1.00 (ref) 8,549 8,487,935 1.00 (ref) 1,861 896,642 1.00 (ref) 
 Asthma only 86 50,590 1.12 (0.90–1.39) 202 206,414 0.98 (0.85–1.12) 40 21,022 0.92 (0.67–1.25) 
 Hay fever only 170 111,342 1.04 (0.89–1.22) 748 892,966 0.94 (0.87–1.01) 199 104,767 1.02 (0.89–1.19) 
 Hay fever and asthma 44 32,186 0.94 (0.69–1.26) 145 191,351 0.86 (0.73–1.01) 44 24,393 0.95 (0.71–1.28) 
Pinteractionc   0.83   0.10   0.89 
Men 
 No asthma or hay fever 2,374 4,233,190 1.00 (ref) 6,074 8,432,777 1.00 (ref) 1,627 816,578 1.00 (ref) 
 Asthma only 93 135,875 1.11 (0.90–1.36) 150 222,298 1.00 (0.85–1.17) 36 20,771 0.92 (0.66–1.28) 
 Hay fever only 206 388,657 1.04 (0.90–1.20) 476 868,136 0.90 (0.82–0.99) 148 94,757 0.93 (0.79–1.11) 
 Hay fever and asthma 44 106,957 0.81 (0.60–1.09) 89 200,398 0.76 (0.62–0.94) 35 22,633 0.92 (0.66–1.28) 
Women 
 No asthma or hay fever 2,591 5,631,425 1.00 (ref) 5,902 11,654,214 1.00 (ref) 1,296 984,851 1.00 (ref) 
 Asthma only 61 151,580 0.82 (0.63–1.05) 152 300,361 1.02 (0.87–1.20) 29 23,457 0.94 (0.65–1.37) 
 Hay fever only 211 610,093 0.91 (0.79–1.05) 602 1,486,482 0.94 (0.86–1.02) 159 133,120 0.99 (0.84–1.17) 
 Hay fever and asthma 64 168,159 0.97 (0.76–1.25) 113 329,169 0.82 (0.68–0.98) 35 31,893 0.90 (0.64–1.26) 
Pinteractionc   0.26   0.66   0.99 
Never smoker 
 No asthma or hay fever 2,504 4,580,901 1.00 (ref) 4,399 8,364,584 1.00 (ref) 1,009 746,143 1.00 (ref) 
 Asthma only 67 111,639 0.98 (0.77–1.25) 110 201,520 1.06 (0.87–1.28) 22 16,872 0.98 (0.64–1.50) 
 Hay fever only 210 497,073 0.95 (0.82–1.09) 480 1,145,024 0.95 (0.87–1.05) 128 109,487 0.96 (0.80–1.15) 
 Hay fever and asthma 65 133,796 1.06 (0.82–1.35) 93 242,000 0.89 (0.73–1.10) 27 24,503 0.89 (0.60–1.30) 
Former smoker 
 No asthma or hay fever 500 914,174 1.00 (ref) 3,439 5,411,919 1.00 (ref) 1,392 777,121 1.00 (ref) 
 Asthma only 13 31,205 0.67 (0.38–1.16) 88 161,631 0.89 (0.72–1.10) 30 20,985 0.82 (0.57–1.18) 
 Hay fever only 50 107,792 0.98 (0.74–1.32) 306 631,797 0.92 (0.82–1.03) 147 90,787 1.02 (0.86–1.21) 
 Hay fever and asthma 32,948 0.57 (0.29–1.10) 57 158,607 0.71 (0.55–0.92) 33 23,041 0.91 (0.64–1.28) 
Current smoker 
 No asthma or hay fever 1,124 3,224,821 1.00 (ref) 2,489 4,098,268 1.00 (ref) 274 144,225 1.00 (ref) 
 Asthma only 47 109,356 1.09 (0.82–1.46) 61 102,513 1.10 (0.85–1.42) 3,191 1.33 (0.66–2.70) 
 Hay fever only 86 285,309 0.97 (0.78–1.21) 156 345,655 0.86 (0.73–1.01) 19 12,481 0.88 (0.55–1.41) 
 Hay fever and asthma 22 78,365 0.91 (0.60–1.39) 31 77,124 0.79 (0.56–1.13) 3,044 0.21 (0.03–1.47) 
Pinteractionc   0.17   0.42   0.15 

aRR for colorectal cancer mortality adjusted for age, sex, race, education, BMI, physical activity, smoking, and aspirin use.

bRR for incident colorectal cancer, adjusted for age, sex, race, education, BMI, physical activity, smoking, aspirin use, and history of colorectal endoscopy.

cInteraction with having both hay fever and asthma compared with neither, as described in Materials and Methods.

In combined analyses of CPS-I and the CPS-II Mortality Cohort that included more than 19,000 colorectal cancer deaths, having both hay fever and asthma, a potential marker of atopy, was associated with approximately 17% lower colorectal cancer mortality. Our results continue to support the association reported in an earlier analysis of the CPS-II Mortality Cohort (4) that included slightly less than half of the colorectal cancer deaths included in the current analysis. It should be noted, however, that our results suggest that the reduction in colorectal cancer mortality associated with having both hay fever and asthma may be smaller than the 24% lower colorectal mortality observed in the earlier CPS-II Mortality Cohort analysis (4). Having both hay fever and asthma was not associated with statistically significantly lower colorectal cancer incidence in the CPS-II Nutrition Cohort (RR = 0.90; 95% CI, 0.71–1.14), although our results are compatible with slightly lower risk.

To our knowledge, only one other study (15) has examined the association between having 2 allergic conditions and risk of colorectal cancer. In an analysis of the IWHS that included 410 incident colorectal cancer cases, having 2 or more allergy-related conditions (potentially including asthma) was associated with considerably lower incidence of colorectal cancer (RR = 0.58; 95% CI, 0.37–0.90; ref. 15). Variation in results in the IWHS and the CPS-II Nutrition Cohort analyses of colorectal cancer incidence could be due to chance or to differences in the information collected on allergic conditions. The IWHS asked about other allergic conditions, such as skin allergies, in addition to hay fever and asthma. However, hay fever and asthma were among the most common allergic conditions in IWHS and had similar associations with colorectal cancer incidence as other allergic conditions. The inverse association between having both hay fever and asthma and colorectal cancer mortality observed in CPS-I and the CPS-II Mortality Cohort, based on relatively large numbers, is compatible with results from the IWHS.

The absence of any important association between either hay fever alone or asthma alone, and colorectal cancer incidence or mortality in this analysis is generally consistent with the results of most previous studies that examined individual allergic conditions, rather than combinations of allergic conditions. A large Taiwanese record linkage study found inverse associations between having either asthma or hay fever and rectal cancer incidence, but no associations with colon cancer incidence (26). Results from that Taiwanese study are consistent with the inverse association between hay fever alone and rectal cancer mortality, but not colon cancer mortality, observed in our analysis. Future analyses of markers of atopy should carefully examine associations by colorectal subsite. Large European record linkage studies comparing colorectal cancer incidence in patients with asthma with that in the underlying general population reported lower risk (16), higher risk (19, 20), and no association (21). Of 6 other studies (1 cohort and 5 case-control) that examined associations with allergic conditions and included at least 100 cases of incident colorectal cancer, 4 reported no association (22–25), 1 reported significantly lower risk with a history of any allergic condition (defined as including asthma; ref. 17), and 1 reported a marginally statistically significant reduction in risk with a history of allergies (not including asthma; ref. 18). The absence of inverse associations with individual allergic conditions in most studies could reflect a weak association between having only one allergic condition and general atopy.

Important strengths of this analysis include its prospective design and large study size. Because of the large size, we were able to examine risk associated with a plausible marker of atopy, having both asthma and hay fever, even though having both conditions is relatively rare. In addition, we were able to adjust for potential confounders, including education and smoking status and to examine results by age, sex, smoking, and colorectal subsite. Several limitations should also be noted. First, analyses of colorectal cancer incidence included considerably less outcomes than analyses of colorectal cancer mortality, limiting our ability to quantify associations with colorectal cancer incidence. Second, asthma and hay fever were self-reported, although CPS-II participants were asked to report physician-diagnosed asthma and hay fever. Asthma and hay fever status may sometimes be misreported, and asthma and hay fever reported, but not diagnosed by a physician, may be less severe than physician-diagnosed asthma or hay fever. Misclassification of asthma and hay fever status could have attenuated our results, particularly in CPS-I, which did not specify that these conditions be physician-diagnosed. In addition, no information was available about age at onset of hay fever or asthma, or about new diagnoses of hay fever or asthma during follow-up. Finally, although analyses were adjusted for multiple colorectal cancer risk factors, we cannot rule out the possibility that the modestly lower risk of colorectal cancer mortality among participants with asthma and hay fever in our study might have been due to residual confounding by health-related behaviors.

In conclusion, results of this analysis of 2 large prospective studies indicate that having both asthma and hay fever, a potential marker of atopy, is associated with modestly lower colorectal cancer mortality. Whether having both hay fever and asthma is associated with colorectal cancer incidence remains unclear. Future research examining associations between colorectal cancer and other potential markers of atopy, such as IgE levels or eosinophil count in prospectively collected blood samples, could clarify the potential importance of IgE-mediated immune reactions in inhibiting colorectal carcinogenesis.

No potential conflicts of interest were disclosed.

Conception and design: E.J. Jacobs, P.T. Campbell

Development of methodology: P.T. Campbell

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S.M. Gapstur, P.T. Campbell

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.J. Jacobs, C.C. Newton, M.C. Turner, P.T. Campbell

Writing, review, and/or revision of the manuscript: E.J. Jacobs, S.M. Gapstur, C.C. Newton, M.C. Turner, P.T. Campbell

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): P.T. Campbell

The authors thank all CPS-I and CPS-II study participants, each member of the study management group and the central cancer registries supported through the Centers for Disease Control and Prevention's National Program of Cancer Registries and cancer registries supported by the National Cancer Institute's Surveillance Epidemiology and End Results Program for their contribution.

The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II Cohort.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Jeffery
PK
,
Haahtela
T
. 
Allergic rhinitis and asthma: inflammation in a one-airway condition
.
BMC Pulm Med
2006
;
6
Suppl 1
:
S5
.
2.
Burrows
B
,
Martinez
FD
,
Halonen
M
,
Barbee
RA
,
Cline
MG
. 
Association of asthma with serum IgE levels and skin-test reactivity to allergens
.
N Engl J Med
1989
;
320
:
271
7
.
3.
Johansson
SG
,
Bieber
T
,
Dahl
R
,
Friedmann
PS
,
Lanier
BQ
,
Lockey
RF
, et al
Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003
.
J Allergy Clin Immunol
2004
;
113
:
832
6
.
4.
Turner
MC
,
Chen
Y
,
Krewski
D
,
Ghadirian
P
,
Thun
MJ
,
Calle
EE
. 
Cancer mortality among US men and women with asthma and hay fever
.
Am J Epidemiol
2005
;
162
:
212
21
.
5.
Jensen-Jarolim
E
,
Achatz
G
,
Turner
MC
,
Karagiannis
S
,
Legrand
F
,
Capron
M
, et al
AllergoOncology: the role of IgE-mediated allergy in cancer
.
Allergy
2008
;
63
:
1255
66
.
6.
Kershaw
MH
,
Darcy
PK
,
Trapani
JA
,
MacGregor
D
,
Smyth
MJ
. 
Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth
.
Oncol Res
1998
;
10
:
133
42
.
7.
Stone
KD
,
Prussin
C
,
Metcalfe
DD
. 
IgE, mast cells, basophils, and eosinophils
.
J Allergy Clin Immunol
2010
;
125
:
S73
80
.
8.
Gatault
S
,
Legrand
F
,
Delbeke
M
,
Loiseau
S
,
Capron
M
. 
Involvement of eosinophils in the anti-tumor response
.
Cancer Immunol Immunother
2012
;
61
:
1527
34
.
9.
Legrand
F
,
Driss
V
,
Delbeke
M
,
Loiseau
S
,
Hermann
E
,
Dombrowicz
D
, et al
Human eosinophils exert TNF-alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells
.
J Immunol
2010
;
185
:
7443
51
.
10.
Moezzi
J
,
Gopalswamy
N
,
Haas
RJ
 Jr
,
Markert
RJ
,
Suryaprasad
S
,
Bhutani
MS
. 
Stromal eosinophilia in colonic epithelial neoplasms
.
Am J Gastroenterol
2000
;
95
:
520
3
.
11.
Fernandez-Acenero
MJ
,
Galindo-Gallego
M
,
Sanz
J
,
Aljama
A
. 
Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma
.
Cancer
2000
;
88
:
1544
8
.
12.
Nielsen
HJ
,
Hansen
U
,
Christensen
IJ
,
Reimert
CM
,
Brunner
N
,
Moesgaard
F
. 
Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue
.
J Pathol
1999
;
189
:
487
95
.
13.
Demirjian
M
,
Rumbyrt
JS
,
Gowda
VC
,
Klaustermeyer
WB
. 
Serum IgE and eosinophil count in allergic rhinitis–analysis using a modified Bayes' theorem
.
Allergol Immunopathol
2012
;
40
:
281
7
.
14.
Prizment
AE
,
Anderson
KE
,
Visvanathan
K
,
Folsom
AR
. 
Inverse association of eosinophil count with colorectal cancer incidence: atherosclerosis risk in communities study
.
Cancer Epidemiol Biomarkers Prev
2011
;
20
:
1861
4
.
15.
Prizment
AE
,
Folsom
AR
,
Cerhan
JR
,
Flood
A
,
Ross
JA
,
Anderson
KE
. 
History of allergy and reduced incidence of colorectal cancer, Iowa Women's Health Study
.
Cancer Epidemiol Biomarkers Prev
2007
;
16
:
2357
62
.
16.
Kallen
B
,
Gunnarskog
J
,
Conradson
TB
. 
Cancer risk in asthmatic subjects selected from hospital discharge registry
.
Eur Respir J
1993
;
6
:
694
7
.
17.
Bosetti
C
,
Talamini
R
,
Franceschi
S
,
Negri
E
,
Giacosa
A
,
La Vecchia
C
. 
Allergy and the risk of selected digestive and laryngeal neoplasms
.
Eur J Cancer Prev
2004
;
13
:
173
6
.
18.
Kune
GA
,
Kune
S
,
Watson
LF
. 
Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study
.
Cancer Res
1988
;
48
:
4399
404
.
19.
Ji
J
,
Shu
X
,
Li
X
,
Sundquist
K
,
Sundquist
J
,
Hemminki
K
. 
Cancer risk in hospitalised asthma patients
.
Br J Cancer
2009
;
100
:
829
33
.
20.
Vesterinen
E
,
Pukkala
E
,
Timonen
T
,
Aromaa
A
. 
Cancer incidence among 78,000 asthmatic patients
.
Int J Epidemiol
1993
;
22
:
976
82
.
21.
Gonzalez-Perez
A
,
Fernandez-Vidaurre
C
,
Rueda
A
,
Rivero
E
,
Garcia
Rodriguez LA
. 
Cancer incidence in a general population of asthma patients
.
Pharmacoepidemiol Drug Saf
2006
;
15
:
131
8
.
22.
Mills
PK
,
Beeson
WL
,
Fraser
GE
,
Phillips
RL
. 
Allergy and cancer: organ site-specific results from the Adventist Health Study
.
Am J Epidemiol
1992
;
136
:
287
95
.
23.
Vena
JE
,
Bona
JR
,
Byers
TE
,
Middleton
E
 Jr
,
Swanson
MK
,
Graham
S
. 
Allergy-related diseases and cancer: an inverse association
.
Am J Epidemiol
1985
;
122
:
66
74
.
24.
Vobecky
J
,
Caro
J
,
Devroede
G
. 
A case-control study of risk factors for large bowel carcinoma
.
Cancer
1983
;
51
:
1958
63
.
25.
Wang
H
,
Rothenbacher
D
,
Low
M
,
Stegmaier
C
,
Brenner
H
,
Diepgen
TL
. 
Atopic diseases, immunoglobulin E and risk of cancer of the prostate, breast, lung and colorectum
.
Int J Cancer
2006
;
119
:
695
701
.
26.
Hwang
CY
,
Chen
YJ
,
Lin
MW
,
Chen
TJ
,
Chu
SY
,
Chen
CC
, et al
Cancer risk in patients with allergic rhinitis, asthma and atopic dermatitis: a nationwide cohort study in Taiwan
.
Int J Cancer
2012
;
130
:
1160
7
.
27.
Garfinkel
L
. 
Selection, follow-up, and analysis in the American Cancer Society prospective studies
.
Natl Cancer Inst Monogr
1985
;
67
:
49
52
.
28.
Hammond
EC
. 
Smoking in relation to the death rates of one million men and women
.
Natl Cancer Inst Monogr
1966
;
19
:
127
204
.
29.
World Health Organization
. 
International Classification of Diseases: Seventh revision
.
Geneva
:
World Health Organization
; 
1957
. p.
81
2
.
30.
Stellman
SD
,
Garfinkel
L
. 
Smoking habits and tar levels in a new American Cancer Society prospective study of 1.2 million men and women
.
J Natl Cancer Inst
1986
;
76
:
1057
63
.
31.
Calle
EE
,
Terrell
DD
. 
Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants
.
Am J Epidemiol
1993
;
137
:
235
41
.
32.
World Health Organization
. 
International Classification of Diseases: Ninth revision
.
Geneva
:
World Health Organization
; 
1977
. p.
107
8
.
33.
World Health Organization
. 
International Statistical Classification of Diseases and Related Health Problems: Tenth Revision
.
Geneva
:
World Health Organization
; 
1992
. p.
192
.
34.
Calle
EE
,
Rodriguez
C
,
Jacobs
EJ
,
Almon
ML
,
Chao
A
,
McCullough
ML
, et al
The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design and baseline characteristics
.
Cancer
2002
;
94
:
2490
501
.
35.
Bergmann
MM
,
Calle
EE
,
Mervis
CA
,
Miracle-McMahill
JL
,
Thun
MJ
,
Heath
CW
. 
Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries
.
Am J Epidemiol
1998
;
147
:
556
62
.
36.
Kleinbaum
DG
. 
Survival Analysis: a Self-Learning Text
.
New York
:
Springer-Verlag
; 
1996
. p.
171
.
37.
Deeks
JJ
,
Altman
DG
,
Bradburn
MJ
. 
Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis
. In:
Egger
M
,
Smith
GD
,
Altman
DG
,
editors
. 
Systemic Reviews in Health Care: Meta-analysis in Context
. 2nd ed.
London, UK
:
BMJ Publication Group
; 
2001
. p.
285
312
.
38.
Scichilone
N
,
Callari
A
,
Augugliaro
G
,
Marchese
M
,
Togias
A
,
Bellia
V
. 
The impact of age on prevalence of positive skin prick tests and specific IgE tests
.
Respir Med
2011
;
105
:
651
8
.
39.
Jensen-Jarolim
E
,
Untersmayr
E
. 
Gender-medicine aspects in allergology
.
Allergy
2008
;
63
:
610
5
.